20041104
 Genzyme Corp.: Rights to Arthritis Medication To Be Reacquired From Wyeth   The Wall Street Journal,  Nov 5, 2004  Genzyme Corp. said it will buy back the rights to sell and market an arthritis pain medication in a deal with Wyeth that could total as much as $415 million.   
